Our work also confirms the low incidence (7/208, 3.37%) of the EML4-ALK translocation among unselected NSCLC patients, which is consistent with the meta-analysis of clinical characteristics associated with the EML4-ALK translocation in the published literature (4.84%). The gene discussed is ALK; the disease is non-small cell lung carcinoma.